Global Reach
LIG-IAGIM Drug Development Association signed close to a 190 generic drug development projects in the 4Q of 2009 and 1Q -3Q of 2010 with generic and innovative drug houses as diverse and far apart as Argentina, Brazil, Canada, China, Denmark, Egypt, France, Germany, Jordan Iran, Ireland, Malta, Malaysia, Mexico, Saudi Arabia, Singapore, South Africa, UK, US and New Zealand.
LocumGroup now fully operational paperless back-office contributed significantly to the rapid and smooth high speed technology transfer process and proved itself to be a winner in cost effective IT process management. As a global print and electronic Journal, Handbook and technology publisher Locum's Paperless e-Office Systems developed and validated over the past five years include rapid and effective auto-invoicing, and client auto-banking to auto-shipping, goods tracking and notification. Included in the paperless e-Office are automatic tax e-filing and staff remuneration, e-insurance, e-pension, e-autobanking, e-salary and e-filing features fully integrated from Locum's Cape Town to Miami operations.
Technology
Leading Generic and Innovative Drug Manufacturers purchased formulation and development, scale-up, validation and commercial IT data, including CMC and Analytical methodology and Bioavailability data profiles from LIG- IAGIM Drug Development Association on an expanding worldwide basis. An interesting development was China's new emergence in purchasing original drug development know-how
by non-state limited liability pharma companies such as Hainan Poly Pharm.
Drug Development
Indian pharma companies have extended and advanced their large drug development product pipeline by purchasing LIG-IAGIM technology dosage form specific handbooks and technical know-how. USV (India). Incepta Bangladesh FamyCare (India) and Randbaxy (India) Wockhardt, Jubilant Organosys (India), Microlabs (India), Tablets India and Ind-Swift have acquired LIG-IAGIM Research and Development technological handbooks and analytical methodology databases covering pre-formulation to scale-up, and commercial manufacturing utilizing IAGIM extended drug development benefit plus plans ranging from periods of 5 -8- 10 years for generic and innovative drug development.
Europe and ME
Product development data in the Middle East region covered critical aspects from formulation technology to large scale development plans. Egypt (Amriya), Jordan (Advance Pharmaceuticals), Iran and Saudi Arabia Jazeera Pharmaceutical Industries manufacturing complex have expanded their modern manufacturing and development facilities. Locum International technology including validated full scale commercial batches in all the proposed marketing strengths enabling companies to slash their generic pipeline queue from 10 -15 months of time saved when compared to formulating from scratch. Locum's advanced modern IT transfer technology reached as far as Lambo (Belgium), Bedi and Fournier France, Alpharma (Denmark), CryoPharma SA (Mexico), KRKA Slovenia, Indonesia's Sanbe Farma (Bandung), Dr Esteces (Spain) Standard Chem and Pharm (Taiwan) and on to eastern Europe via Ukraine's Hexal operations in Kiev.
Workshops and Drug Development Expositions [US EXPO]
IAGIM continued to advance and spread it's state-of-the-art drug development know-how and validated commercial sized manufacturing technology to the four corners of the earth in approximately 110 countries. A new development was highlighted in the P.R. of China (PolyPharm) incorporating additional western high tech based technology and guidelines. IAGIM conducted regular drug development formulation seminars symposia and workshops in all five continents. The annual CT and US drug development Exposition (CT, US EXPO) drew in large interested clientele from every continent, as well as major generic and innovative drug development companies, research laboratories and big pharma consultants.
Asia Technology
India has maintained its' status and lead as a major technology purchaser of LIG-IAGIM information technology (IT) and drug development know-how covering all aspects from A-Z of Locum's databases.
Major Indian drug houses such as Adjunta, Centaur Pharmaceutical, CadilaPharm, GlaxoSmithKline (Philippines), Indoco, IPCA, JB Chemicals and Pharmaceuticals, RatioPharm, Orchid, Cipla, Novartis, Nicholas Piramal, Randbaxy, Strides Arcolabs, Sun Pharma, USV, Wockhardt and Dr. Reddys have expanded their state-of-the-art international level operations and advanced research, development and manufacturing capabilities utilizing key aspects of Locum International Group's generic and innovative drug development, HPLC + UV validated analytical methodology, development e-SOP and FDA and EU level commercial manufacturing technology to their product export advantage..
Global Technology
Locum International Research Ltd., is headquarters in Israel, Locum International Inc. in Florida USA and Locum International Group Switzerland. The Group is among the top pharmaceutical generic pharmaceutical drug development company in the world. The company researches and develops generic formulations, manufacturing processes, scale-up and validation commercial sized procedures and markets generic and innovative controlled release and sterile pharmaceuticals as well as active pharmaceutical ingredients know-how and technology, such as the neurobiological innovative drugs (F-CRAB's, CMZ CR) worldwide in over a 175+ countries. LIG provides and presents leading FDA and EU approved SOPs, PAIs, analytical methods, ANDAs, dossiers, seminars, workshops and conferences worldwide, covering both pharmaceutical and neurobiology (F-CRAB's).
Neurobiological Development - F-CRAB's / CMZ CR
LI neurobiology development and experimental unit is currently developing advanced default protein folding mechanisms and routes for the F-CRAB RRMS drugs (relapsing remitting multiple sclerosis family of drugs), which include the development of the second generation Glatiramer Acetate Copoxane2 (COP2), with special reference to the molecular weight spectrum (Av.25+nK daltons spread and limits/10+nK->25+nK) of the truncated four amino-acid glatiramer acetate complex, which has a significant batch-2-batch (B2B-SV+RSD) synthesis variation, requiring advanced cGMP and QA/QC controls, that differ significantly from the normal drug synthesis pathways, especially in intermediate QA testing of the protected intermediates. Impeccable cleaning validation, stringent controls of starting, intermediate raw materials and solvents, resulting in significantly tighter batch to batch variations and B2B RSD's and impurity profiles, using special HPLC column and gel-filtration analytical methodology techniques.
Innovative Research
Workshops, lectures and seminars on the F-CRAB RRMS drugs, their development, synthesis, formulation, proposed default 'protein' folding, HPLC / gel filtration analysis/A.M validation and associated e-CTD/CTD specification / parameters are available as per advertised timetable in both EU and the US journal series (Contact LIG). The International Journal of Drug Development (IJDD Vol. 10/11) and the International Journal of Drug R&D (IJDR&D Vol. 11/12) are the main current print venues in the International Journal Series for publishing the ongoing F-CRAB RRMS drug innovation, experimental research and product development. Other venues include International Journal of Drug cGMP (IJGMP) and International Journal of Drug Validation (IJDV) and International Journal of Drug Master Formula and Processes (IJDM&P).
Market Highlights
Over 85% of Locum's technology sales are in Asia/China/Japan (39), North America (31) and Europe (30). For additional information contact LIGroup (www.LocumUSA.com) or IAGIM (www.iagim.org) or use the LIG international tel/voice messaging system US +1-561-865-6147

Pharma Today, International Journal of Generic Drugs, Times of India, Mail and Guardian Washington Post and Times

New Food and Wine GMP Journal and New Food and Wine R&D Journal.
Locum International Press - publishers of the renown, peer reviewed international journal series on innovative and generic drug development have initiated their first pre-marketing of their two new International Journals on Food & Wine cGMP and Food & Wine R&D. Structured as a 80p full color, glossy, technical, hands-on, state-of-the-art, international Good Manufacturing Practice publication, the Journal fills a long awaited gap in the food and wine technology markets

The first three special editions are dedicated to champagne manufacture, tips and traps, Do's and Don'ts with a very special emphasis on the Method Cap Classique Technology. Packed with case studies, processing QC tabulations and flowcharts. The IAGIM Association web site highlights the table of contents for the first three US Special Editions located at http://www.iagim.org/wine

Locum offers wine researches and developer an extensive membership online archive available for an annual membership fee, similar in design and function to the authoritative drug development center at IAGIM.org

The 2004 special edition is marketed and sold by some 140 of LIG own agencies in some 139 countries. The initial marketing and sales debut targeted for December 2002 (New Year Special First Edition. Distribution formats available will be initially in glossy print (Color & B/W) and CD ROM.

The US Internet online edition is scheduled for January 2004. Initial early bird subscriptions of this unusual journal priced at $699 for 8 issues per annum has already reached over the 800 mark of some of the worlds top Food, Pharmaceutical and Wine manufacturers with a 2004 first quarter projected target circulation of 2800 - 3200 issues covering some 140 000 readers worldwide.

An introductory offer of three (3) issues for $799 ea. is available until December 2003 when all special promotions on the web close. Contact LIG via http://www.locumUSA.com or worldwide fax at + US Tel. +1-561-865-6147

International Journal Series / Pharma Technology / Vision in Business

IAGIM Drug Development Association signed close to a dozen generic drug development projects in the 1Q of this year with generic houses as diverse as Argentina, Brazil, China, Ireland, Malaysia, Singapore, US, UK, and New Zealand. Leading Generic Drug Manufacturers purchased IT data, including CMC and Analytical and Bioavailability data profiles from IAGIM Association.

Isofarma (Brazil) has extended its well known sterile products and entered the Brazilian generic tablet and capsule market by purchasing IAGIM full CMC data packages. The Norton (UK), Ivax (Ireland) and Zenith Goldline (US) top selling generic lines derived several of their key product know-how from the IAGIM Research and Development laboratories and scale-up manufacturing units utilizing IAGIM extended benefit plans for generic and innovative developers.

Product development data supplied up to validated full scale commercial batches in all the proposed marketing strengths slashed the companies generic pipeline queue from 9 -15 months of time saved in formulating from scratch.. Within 89 days from IT transfer IAGIM's Tamoxifen 10,20, 30 & 40 mg passes Ivax's US / EU bioequivalent study.

Most of the current pipeline projects are based on research performed in the leading research institutes and licensed pharma companies in US, Asia, EU, Japan, RSA and US. With the acquisition of IAGIM Research at the beginning of 1999, LIG's development pipeline has been enriched with several new controlled / modified release tablet and capsule products.
IAGIM has spread it's state-of-the-art drug development know-how and manufacturing technology in approximately 70 countries with regular drug development/formulation seminars and workshops conducted on all five continents. India has become a major purchaser of IAGIM information technology (IT) counting major Indian drug houses as Cipla, Novartis, Nicholas Piramal, Ranbaxy, Sun, Wochardt and Dr. Reddys.

For additional information contact IAGIM http://www.iagim.org | Tel.. US +1-561-865-6147

Pharma Today

IAGIM Drug Development Association has placed its latest Active Pharmaceutical Ingredient Database of over 16000 active ingredient manufacturers on its drug development web site. Rapid searches (up to 60 data lines to the public and over 180 lines per screen to IAGIM members) for any FDA registered active ingredient and corresponding manufacturing site can be made within a few seconds. Locum's sophisticated search engine and data base is one of the web most advanced search system. The database may be accessed at http://www.iagim.org/search. Data base was outlined at the Singapore Drug Development Conference 2000. Contact IAGIM via http://www.iagim.org or Tel. +1-561-865-6147
Pharma Today

Both the International Journal of Generic Drugs (IJGD) and the International Journal of Drug Development (IJDD) publishes articles, reviews and papers on all aspects of generic and innovative drug development from pre-formulation to aspects of regulatory strategy. The IJGD includes special reference to on-time development on ANDA submissions and the IJDD includes references to the on-time development of EU Dossiers, NDA and ANDA submissions. Locum has been engaged in innovative research and development for almost two decades now. During this period, it has made significant progress, mainly in two therapeutic fields: controlled release mechanisms (CE/MR/SR), with particular emphasis on matrix tablet formulations(MF), and sterile product technology. Soft Gelatin Capsule development has recently emerged as a potential new area for a variety of active ingredients formulations and commercial procedures. For additional details contact Locum International, www.locumusa.com, www.locumeuro.com,
Tel. +1-561-865-6147
VIB - Brussels Belgium

32.7 Unique Pharmaceutical Service.
Locum International LTD specializes in services which have been upgraded and expanded to International Regulatory Standards including many innovative plans and systems gathered by the company's International team regarding cGMP, GLP, Validation, QC, QA, Marketing and Post Marketing Surveillance. The company states that they create an international foundation for companies to widen sales and marketing vistas. The company specializes in FDA and DHSS hardware and software conversions; provides full teaching and training programs to the inexperienced line worker at all operating levels; and full formulation and registration new products including updating and maintenance of current registration dossiers to meet the ongoing pharmacopoeia and cGMP changes. Locum has been engaged in innovative research and development for almost two decades now. During this period, it has made significant progress, mainly in two therapeutic fields: controlled release mechanisms (CE/MR/SR), with particular emphasis on matrix tablet formulations(MF), and sterile product technology. Soft Gelatin Capsule development has recently emerged as a potential new area for a variety of active ingredients formulations and commercial procedures.

LOCUM has been offering their services in South Africa providing a World Class Facility.
ICEN - The Israel Commercial Economic Newsletter.

The International Journal of Generic Drugs, published by Locum International Publishers and featuring articles on generic drug development and manufacturing, quality control and assurance, and bulk pharmaceutical chemicals, has placed the Table of Contents of its 1996 issues on the Internet. It can be accessed via the publisher's home page at : http://www.locum.co.il. Further details are available from Dr. Jeremy David Block Editor Locum International Press
Script - Richmond UK